Briggs Morrison, M.D.
Dr. Briggs W. Morrison is the CEO and a Board Director of Syndax Pharmaceuticals (NASDAQ: SNDX), an MPM portfolio company. Briggs serves on the board of MPM portfolio companies Oncorus (NASDAQ: ONCR), Repare Therapeutics (NASDAQ: RPTX), Twentyeight-Seven Therapeutics and Werewolf Therapeutics. Briggs is also an investment committee member of the UBS Oncology Impact Fund (OIF), an oncology-only crossover fund (both private and public equities) managed by MPM.
Prior to joining MPM, Briggs served as Chief Medical Officer and Executive Vice President for Global Medicines Development at AstraZeneca. His career also includes distinguished roles at Pfizer and Merck. As Head of Global Medicines Development at AstraZeneca, he oversaw all clinical development functions and late-stage clinical development projects. As Head of Clinical Development at Pfizer, he oversaw Phase 1-3 development and operations for all therapeutic areas before being appointed the Head of Development, Medical Affairs, Safety and Regulatory Affairs for all Pfizer human health businesses. Briggs has overseen the development of numerous biopharmaceutical products in multiple therapeutic areas, such as LYMPARZA® and TAGRISSO®. He was also the former Chairman of Transcelerate BioPharma, an industry-funded company charged with improving aspects of clinical trials.
Briggs earned his M.D. from the University of Connecticut and completed his training in Internal Medicine at Massachusetts General Hospital and in Medical Oncology at the Dana-Farber Cancer Institute. He also completed a post-doctoral research fellowship in the Department of Genetics at Harvard Medical School and additional post-doctoral work at the Dana-Farber Cancer Institute. He received his B.S. in Biology from Georgetown University.